Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
If you are wondering whether Praxis Precision Medicines is still priced attractively after its big run, this article will walk through what that current share price could imply about the company. The stock recently closed at US$293.95, with a 1 year return that is very large and a 2.6% gain year to date, even though the last 7 days and 30 days have seen returns of 5.4% and 7.3% declines. Recent market attention around Praxis, including coverage of its progress as a clinical stage neuroscience company and updates on its development pipeline, has helped frame expectations around future prospects. At the same time, investors have been reacting to news flow around regulatory milestones and trial updates that often influence risk perceptions for biotech names. Simply Wall St currently gives Praxis Precision Medicines a valuation score of 3 out of 6 . Next, we will walk through what different valuation approaches suggest about that price, and then finish with a broader way to think a
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines (PRAX) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit [Yahoo! Finance]Yahoo! Finance
- Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? [Yahoo! Finance]Yahoo! Finance
- This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter [Yahoo! Finance]Yahoo! Finance
- Praxis FDA Filings Shift Focus From Pipeline Promise To Potential Revenue [Yahoo! Finance]Yahoo! Finance
PRAX
Earnings
- 2/19/26 - Miss
PRAX
Sec Filings
- 2/19/26 - Form S-8
- 2/19/26 - Form 10-K
- 2/19/26 - Form 8-K
- PRAX's page on the SEC website